REG - Oncimmune Hldngs PLC - Notice of Trading Update

Oncimmune HoldingsAnnouncement

29/05/2020 07:00

RNS Number : 2712O
  
Oncimmune Holdings PLC
  
29 May 2020
  
 

29 May 2020 
 
 
Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
 Notice of Trading Update
 
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, will be announcing a trading update for the full year ended 31 May 2020 on Thursday, 4 June 2020.
 
Dr Adam M Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, and Professor Tariq Sethi, Chief Scientific Officer, will host an online presentation and conference call for analysts and investors at 10:30am BST on 4 June 2020.
 
The Company will also be conducting live virtual laboratory tours with lead scientists at its sites in Nottingham, UK and Dortmund, Germany. This will provide the attendees with a rare insight into the science behind Oncimmune's EarlyCDT tests and its core immune profiling technology service, ImmunoINSIGHTS.
 
For video conference details please contact Alex Davis at FTI Consulting at alexander.davis@fticonsulting.com or 020 3727 1000. 
 
 
For further information:
 
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
 
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
 
finnCap (Joint Broker)
Geoff Nash, Matthew Radley, Tim Redfern
+44 (0)20 7220 0500
 
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
 
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
oncimmune@fticonsulting.com
+44 (0)20 3727 1000
 
 
About Oncimmune
 
Beating cancer, one test at a time
 
The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.
 
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT® Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.
 
Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
 
What is EarlyCDT?
 
EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells. EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor's surgery.
 
Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).
 
What is ImmunoINSIGHTS?
 
The ImmunoINSIGHTS service leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling enhanced development of targeted and more effective treatments. 
 
For more information, visit www.oncimmune.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
NORFLFFEETITFII